Triple Negative Breast Cancer (TNBC)

There is a significant unmet need for new, safer, and more effective treatments for TNBC, which has high rate of resistance, recurrence, and very low survival rates. NMX1 represents a first-in-class drug candidate that has effectively treated primary and metastatic TNBC as a single agent and in combination with other cancer drugs (including doxorubicin as well as checkpoint inhibitors) in animal models by blocking the pro-survival and immune suppressive effects of the tumor microenvironment that drive cancer progression. In addition, NMX1 reduces chemotherapy-induced cardiotoxicity and thereby holds significant potential to improve survival and long term outcomes for TNBC patients.

Fibrosis

IL-11 is significantly upregulated in invasive fibroblasts in Idiopathic Pulmonary Fibrosis (IPF) and is increasingly recognized as key determinant of lung fibrosis, inflammation, and epithelial dysfunctions. NMX2 is our lead fibrosis drug candidate that prevents and reverses established fibrosis and inflammation in aggressive pre-clinical models of lung and liver fibrosis, through the inhibition of IL-11 and pro-inflammatory cytokine production. It has also shown compelling synergistic effects pre-clinically with two of the leading fibrosis drugs on the market today, Esbriet® and OFEV®.

Cardio-Oncology

Cardio-Oncology is an emerging subspecialty that addresses the profound effects of malignancies and oncological treatments on the cardiovascular system that often lead to heart failure mortality. While cardiovascular damage can occur with numerous cancer therapies, anthracyclines like doxorubicin (DOX, Adriamycin), the frontline treatment for TNBC, are best known to cause dose-dependent, delayed, and progressive cardiomyopathy, often years after treatment. Therefore, the leading cause of death in breast cancer survivors is cardiovascular disease, caused by the same treatment that once saved their lives. Additionally, many patients cannot endure many potential life-saving cancer treatments due to reduced cardiovascular health.

NovoMedix’s NMX1 is an oral small molecule drug that co-targets key pathways with anti-cancer as well as cardioprotective properties. Preclinical data shows that these molecules have synergistic properties in both primary and metastatic TNBC tumors when used in combination with chemotherapeutic and immune oncology agents while protecting cardiomyocytes and preserving cardiac function. This unique property derived from the co-targeting activity of NovoMedix's drug candidates has potential to significantly improve the clinical outcome of patients as well as the longevity and quality-of-life of breast cancer survivors.